Novacap, a global player in the pharmaceutical and cosmetics industry, announces the acquisition of ID bio, a producer of natural active ingredients for the cosmetics industry, as well as H2B, a manufacturer of blood fractionation products for in vitro diagnostics.
The Novacap group serves the cosmetic industry through essential ingredients used as preservatives, UV filters, exfoliants and fragrances.
ID bio puts its expertise in enzymatic extraction and purification at the service of innovation, in order to strengthen its catalog of active ingredients and botanical extracts. ID bio relies on ethical sourcing of raw materials, selected in an eco-responsible manner, in order to offer differentiated ingredients with controlled traceability.
The acquisition of ID bio by Novacap is fully in line with the group's growth strategy which aims to offer its customers a wide range of active and functional ingredients and to expand its portfolio of cosmetic ingredients with products of natural origin.
H2B, ID bio's sister company, will strengthen the Novacap Group's position in the Pharmaceutical and Healthcare markets.
"The innovation and development capabilities of ID bio and H2B enrich Novacap's offer, as well as its ability to meet the requirements of its strategic clients", says Pierre Luzeau, President of Novacap.
"Joining Novacap will allow ID bio and H2B to accelerate their development by pooling our market approaches and recognized expertise. The complementarities between our two groups open up great prospects for the future of both companies," said Jean-Pierre Picot, President and founder of ID bio.
With this alliance, ID bio and H2B will be able to leverage Novacap's industrial and regulatory expertise, as well as its broad customer portfolio, to accelerate their growth.
